Structure of Selumetinib
CAS No.: 606143-52-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Selumetinib (AZD6244) is a selective, non-ATP-competitive oral MEK1/2 inhibitor with an IC50 of 14 nM for MEK1, and it inhibits ERK1/2 phosphorylation.
Synonyms: AZD6244; ARRY-142886; ARRY886
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Raúl Garde Casasnovas ;
Abstract: Resumen: In this thesis three calibration approaches applied to high resolution continuum source graphite furnace atomic/molecular absorption spectrometry (HR CS GF AAS/MAS) have been studied. The advantages of multi-energy calibration for Br determination using Ca by monitoring the molecule CaBr have been assessed and compared with a similar approach developed during this study called multi energy ratios (MER). MER Data treatment does not require linear regression, and a dispersion of ratios between sample and sample+spike is calculated, this relationship is equivalent to the slope calculated in MEC. Since the basis mathematical relationship of this methodology is not linear, accuracy and precision of the method depend on the relative amounts of sample and amount of spike added. Better results were observed if the ratios/slope between signals of sample and saple+spike were near 0.5. results of MEC and MER were compared at two transitions of CaBr, Χ2Σ → A2Π (0,0) y Χ2Σ → B2 Σ(1,0), showing that for similar molecular transition sensitivities, MER is a more reliable strategy. If the number of transitions is high and with different sensitivities, MEC provides better precision. Besides, a method for the calculus of the limits of detection and quantification using MER, which allows to identify if the lines have the sensitivity needed for its application. Despite a wavy background around 625 nm, and the presence of an unknown molecule, the measurements of a certified reference material QC3060 showed accurate results for Br. The capabilities of a machine learning algorithm (ML) for the determination of halogen proportions in active pharmaceutical ingredients (API) by means of a modular simultaneous echelle spectrograph (MOSES) prototype, capable of increase the spectral window 100 times the values found in commercial continuum source instruments, coupled to a contrAA800G. Due to the univariate nature of the tree boosting algorithm, three models for F, Cl and Br each were calculated. Br model showed a bad performance, and it was decided to calculate its concentration through the remaining fraction. Validation parameters (Venetian blinds with ten splits and root mean square error of calibration, RMSEC) along with the four CRM proportions, which have variable quantities of the three halogens of interest, have shown the correct performance of the ML model. Additionally, MER was applied for the determination of F in these samples,.with errors under 5%. Afterwards, according to the proportions provided by the XGboost model and F concentration determined using MER, Br and Cl concentrations were determined, with errors under 10%. In this study, nanoparticles (NPs) and core-shell nanoparticles (SNPs) have been analyzed in order to identify between the atomization processes of NPs and ions of Cu, Pt, SiO2, Au and Ag by means of HR CS GF AAS. Thus, a parameter called tdelay (atomization delay) was used, Absorbance spectra of NPs and ions of these elements did not show differences at any of the ramps studied. However, Au and Ag did show differences in their tedlay, calculated using a peak fit strategy. Au showed a unimodal signal for NPs following a Voigt profile,on the other hand, Au ions presented from one to two peaks, depending on the state of the tube. Ag, on the contrary, showed a complex signal for every specie analyzed, adjusting better for three Gaussian peaks. The analysis of mixtures of Au showed that only a few mixtures with high differing masses presented a double peak. The rest of the mixtures appear as a unimodal signal. In both cases, size was estimated comparing their tdelay with pure AuNPs. Results show variable errors but iut seems that mixtures with significantly differing sizes provided size values closer to the expected ones. No mixture of AgNPs showed a bimodal peak. Hence, size was compared to the average size and average volume of NPs. Ag results presented lower error, except for a mixture with -19%, all mixtures showed less than 10% error in size relative to the average size. CSNP measurements showed that size estimated using the shell if it is comprised of Au and Ag, provided similar results to the overall size of the CSNPS. Core size characterization, on the other hand, showed errors around 20%. CSNPs smaller of 20 nm presented a high error and imprecision. Lastly, the effect of the presence of silica in the structure of CSNPs with Au was assessed. In Au@SiNPs, Au-core atomizes much later than expected according to previous experiments, with a different peak profile. Si@AuNPs, Res660, Res800 and Res980, were analyzed to calculate the size of the Au structure (shell). However, these CSNPs are larger than the standards measured, and results were calculated by extrapolation. Errors between -20 and 20% were achieved, relatively good values were achieved for extrapolated data. Finally, Si-core was estimated in Si@AuNPs through the difference of the total volume of the CSNP (estimated experimentally sizing the Au-shell) and the volume of atoms of the shell occupied (volume per concentration of Au in the sample including the particle number, provided by the manufacturer).
Show More >
CAS No. : | 606143-52-6 |
Formula : | C17H15BrClFN4O3 |
M.W : | 457.68 |
SMILES Code : | O=C(C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C3N=CN(C)C3=C1)NOCCO |
Synonyms : |
AZD6244; ARRY-142886; ARRY886
|
MDL No. : | MFCD11977472 |
InChI Key : | CYOHGALHFOKKQC-UHFFFAOYSA-N |
Pubchem ID : | 10127622 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H332-H335 |
Precautionary Statements: | P261-P280-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
NF1-mutant NF95.11b neuro fibroma cells | 1 μM | 48 h | To test if PRC2 inactivation is sufficient for selumetinib resistance, results showed that PRC2 inactivation inhibited Schwann cell differentiation marker expression and attenuated selumetinib responses. | PMC10786885 |
Human monocyte-derived dendritic cells (mDC) | 1 μM | 48 h | Selumetinib increased the expression of activation markers CD80, CD83, CD86, and HLA-DR on mDCs. | PMC5557252 |
CT26 murine colon adenocarcinoma cells | 0.123 μM | 48 h | Selumetinib increased the expression of H2-Kd class-I MHC proteins and decreased PD-L1 expression in CT26 cells. | PMC5557252 |
Human peripheral blood mononuclear cells (PBMC) | 5.8 nM (IC50) | 72 h | Selumetinib inhibited T-cell activation and reduced IL-2 secretion. | PMC5557252 |
A172 cells | 10 nM | 24 h | To evaluate the inhibitory effect of Selumetinib on GBM cell proliferation. The results showed that Selumetinib significantly inhibited TRIM22 overexpression-induced GBM cell proliferation. | PMC10318069 |
U251MG cells | 10 nM | 24 h | To evaluate the inhibitory effect of Selumetinib on GBM cell proliferation. The results showed that Selumetinib significantly inhibited TRIM22 overexpression-induced GBM cell proliferation. | PMC10318069 |
Primary astrocytes | 1 μM | 48 h | To study the effect of Selumetinib on the activity of primary astrocytes, the results showed that Selumetinib did not affect cell activity. | PMC8922810 |
SUM149 | 0.1 μM and 1 μM | 48 h | To evaluate the effect of Selumetinib on cell cycle distribution, results showed that Selumetinib induced G1 arrest. | PMC4674314 |
MDA-MB-231 | 0.1 μM and 1 μM | 48 h | To evaluate the effect of Selumetinib on cell cycle distribution, results showed that Selumetinib induced G1 arrest. | PMC4674314 |
SUM149 | 0.001, 0.01, 0.1, 1, or 10 μM | 72 h | To evaluate the effect of Selumetinib on cell proliferation, results showed that Selumetinib did not significantly inhibit cell proliferation in 2D culture. | PMC4674314 |
MDA-MB-231 | 0.001, 0.01, 0.1, 1, or 10 μM | 72 h | To evaluate the effect of Selumetinib on cell proliferation, results showed that Selumetinib did not significantly inhibit cell proliferation in 2D culture. | PMC4674314 |
NF1-deficient human Schwann cells | 10-100 nM | 48 h | To evaluate the cytotoxic effect of CQ on NF1-deficient human Schwann cells, results showed that CQ significantly reduced the viability of NF1/C0//C0 cells. | PMC11887668 |
NF1-deficient Drosophila cells | 1-10 µM | 48 h | To evaluate the cytotoxic effect of CQ on NF1-deficient cells, results showed that CQ significantly reduced the viability of dNF1-KO cells. | PMC11887668 |
A549 cells | 1 μM | 24 hours | To study the effect of MEK inhibitors on KRAS-mutant lung cancer cells, it was found that MEK inhibitors including GDC-0623 enhanced HGF- and EGF-induced AKT phosphorylation. | PMC5065770 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | JW23.3 MPNST allograft model | Oral | 25 mg/kg | Twice daily for 21 days | To test the in vivo efficacy of Selumetinib, results showed that Selumetinib significantly inhibited the growth of MPNST allografts. | PMC10786885 |
Mice | CT26 murine colorectal cancer model | Oral | 25 mg/kg | Twice daily for 8 days | Selumetinib reduced CD11b+Ly6G+ granulocytic cells in the tumor microenvironment, increased the frequency of CD11b+Ly6C+MHCII+ intermediate differentiating monocytes, and decreased the expression of Cox-2 and Arg1. | PMC5557252 |
NOD/SCID mice | GBM xenograft model | Intraperitoneal injection | 50 mg/kg | Daily until the end of the experiment | To evaluate the inhibitory effect of Selumetinib on GBM tumor growth. The results showed that Selumetinib significantly inhibited TRIM22 overexpression-induced GBM tumor growth and prolonged the survival of mice. | PMC10318069 |
Mice | Intracerebral hemorrhage model | In situ injection | 5 mg/kg | Single injection, lasting 10 minutes | To study the therapeutic effect of Selumetinib on mice with intracerebral hemorrhage model, the results showed that Selumetinib improved the pathological indices and prognosis after intracerebral hemorrhage. | PMC8922810 |
Female athymic nude mice | Triple-negative breast cancer xenograft model | Oral | 50 mg/kg | Daily for 3 weeks | To evaluate the inhibitory effect of Selumetinib on lung metastasis, results showed that Selumetinib significantly reduced the incidence of lung metastasis. | PMC4674314 |
Mice | NF1-deficient MPNST xenograft model | Intraperitoneal injection | 50 mg/kg | Three times per week for 3 weeks | To evaluate the inhibitory effect of CQ on NF1-deficient tumors, results showed that CQ significantly slowed tumor growth, and the effect was superior to Selumetinib. | PMC11887668 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00085787 | Advanced Cancer | Phase 1 | Completed | - | United States, Colorado ... More >> University of Colorado Cancer Center, Anschutz Cancer Center Aurora, Colorado, United States, 80010 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less << |
NCT00780676 | Breast Cancer | Phase 2 | Terminated(Closed early for fu... More >>tility.) Less << | - | United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT02546661 | Muscle Invasive Bladder Cancer | Phase 1 | Recruiting | March 27, 2020 | - |
NCT00780676 | - | Terminated(Closed early for fu... More >>tility.) Less << | - | - | |
NCT02179671 | Locally Advanced or Metastatic... More >> Non-Small-Cell Lung Cancer (Stage IIIB-IV) Less << | Phase 2 | Completed | - | United States, Arizona ... More >> Research Site Goodyear, Arizona, United States United States, District of Columbia Research Site Washington, District of Columbia, United States United States, Georgia Research Site Augusta, Georgia, United States Research Site Marietta, Georgia, United States United States, Kentucky Research Site Ashland, Kentucky, United States United States, Missouri Research Site St Louis, Missouri, United States United States, New York Research Site Mineola, New York, United States United States, North Carolina Research Site Huntersville, North Carolina, United States United States, Washington Research Site Spokane, Washington, United States Research Site Tacoma, Washington, United States Less << |
NCT01229150 | Non Small Cell Lung Carcinoma | Phase 2 | Completed | - | United States, California ... More >> University of California, Davis Davis, California, United States, 95616 University of Southern California Health Sciences Campus Los Angeles, California, United States, 90033 City of Hope Medical Group South Pasadena, California, United States, 91030 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
NCT00936221 | Melanoma | Phase 2 | Completed | - | - |
NCT01229150 | - | Completed | - | - | |
NCT00936221 | - | Completed | - | - | |
NCT01134601 | Non-Metastatic Adenocarcinoma ... More >>of the Rectum Less << | Phase 1 | Terminated | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
NCT01160926 | Rectal Cancer | Phase 1 | Terminated(2 DLTs had been rep... More >>orted from first 4 patients on lowest possible dose cohort.) Less << | September 2016 | United Kingdom ... More >> The Christie NHS Foundation Trust Manchester, United Kingdom, M20 4BX Less << |
NCT01750281 | Locally Advanced or Metastatic... More >> Non Small Cell Lung Cancer Stage IIIb - IV Less << | Phase 2 | Active, not recruiting | December 31, 2018 | - |
NCT02143466 | Advanced Non Small Cell Lung C... More >>ancer Less << | Phase 1 | Recruiting | December 30, 2019 | - |
NCT00866177 | Recurrent Melanoma ... More >> Stage III Skin Melanoma Stage IV Skin Melanoma Less << | Phase 2 | Completed | - | United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less << |
NCT01287130 | Colonic Neoplasms ... More >> Cancer of the Colon Colon Cancer Colon Neoplasms Colonic Cancer Less << | Phase 1 | Completed | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
NCT00710515 | Melanoma|Malignant Melanoma | PHASE1 | COMPLETED | 2025-06-10 | Research Site, Amsterdam, Neth... More >>erlands|Research Site, Maastricht, Netherlands|Research Site, Glasgow, United Kingdom|Research Site, Headington, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom Less << |
NCT01750281 | - | Active, not recruiting | - | - | |
NCT01143402 | - | Completed | - | - | |
NCT00866177 | - | Completed | - | - | |
NCT01166126 | Mucosal Melanoma ... More >> Recurrent Melanoma Stage IV Melanoma Less << | Phase 2 | Terminated | - | United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less << |
NCT00890825 | - | Completed | - | - | |
NCT01166126 | - | Terminated | - | - | |
NCT00514761 | Metastatic Colorectal Cancer | Phase 2 | Completed | - | Brazil ... More >> Research Site Goiania, Brazil Research Site Rio de Janeiro, Brazil Research Site Sao Paulo, Brazil Less << |
NCT01256359 | Melanoma | Phase 2 | Active, not recruiting | December 2018 | United Kingdom ... More >> Churchill Hospital Oxford, Oxfordshire, United Kingdom, OX3 7LJ Less << |
NCT00372944 | Pancreatic Cancer | Phase 2 | Completed | - | United States, California ... More >> Research Site Alhambra, California, United States Research Site Bakersfield, California, United States Research Site Palm Springs, California, United States Research Site Santa Maria, California, United States United States, Florida Research Site Orlando, Florida, United States United States, Maryland Research Site Chevy Chase, Maryland, United States United States, Michigan Research Site Ann Arbor, Michigan, United States United States, New York Research Site New York, New York, United States United States, Tennessee Research Site Nashville, Tennessee, United States United States, Texas Research Site Temple, Texas, United States United States, Washington Research Site Seattle, Washington, United States Australia Research Site Heidelburg, Australia Bulgaria Research Site Plovdiv, Bulgaria Research Site Sofia, Bulgaria Research Site Varna, Bulgaria Hungary Research Site Budapest, Hungary Romania Research Site Cluj-Napoca, Romania Less << |
NCT00890825 | Non Small Cell Lung Cancer | Phase 2 | Completed | - | - |
NCT00600496 | Breast Cancer ... More >> Breast Neoplasms Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer Less << | Phase 1 | Active, not recruiting | December 31, 2018 | United States, Michigan ... More >> Research Site Detroit, Michigan, United States, 48201 United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Research Site Nashville, Tennessee, United States, 37203 United States, Texas Research Site Houston, Texas, United States, 77030 Less << |
NCT00372788 | Non-small Cell Lung Cancer | Phase 2 | Completed | - | United States, California ... More >> Research Site Los Angeles, California, United States United States, Michigan Research Site Ann Arbor, Michigan, United States United States, New York Research Site New York, New York, United States United States, Tennessee Research Site Nashville, Tennessee, United States Bulgaria Research Site Plovdiv, Bulgaria Research Site Sofia, Bulgaria Research Site Varna, Bulgaria Romania Research Site Cluj-Napoca, Romania Less << |
NCT01143402 | Iris Melanoma ... More >> Medium/Large Size Posterior Uveal Melanoma Ocular Melanoma With Extraocular Extension Recurrent Uveal Melanoma Small Size Posterior Uveal Melanoma Stage IV Uveal Melanoma Less << | Phase 2 | Completed | - | - |
NCT01658943 | - | Completed | - | - | |
NCT01021748 | Locally Advanced or Metastatic... More >> Solid Tumors Less << | Phase 1 | Completed | - | - |
NCT00970359 | - | Completed | - | - | |
NCT01658943 | Pancreatic Acinar Cell Carcino... More >>ma Pancreatic Ductal Adenocarcinoma Recurrent Pancreatic Carcinoma Stage IV Pancreatic Cancer Less << | Phase 2 | Completed | - | - |
NCT01313039 | - | Completed | - | - | |
NCT00970359 | Thyroid Cancer | Not Applicable | Completed | - | United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less << |
NCT01021748 | - | Completed | - | - | |
NCT00338130 | Melanoma | Phase 2 | Completed | - | - |
NCT01859182 | Adenocarcinoma of the Gallblad... More >>der Adenocarcinoma With Squamous Metaplasia of the Gallbladder Adult Primary Cholangiocellular Carcinoma Advanced Adult Primary Liver Cancer Cholangiocarcinoma of the Extrahepatic Bile Duct Localized Unresectable Adult Primary Liver Cancer Metastatic Extrahepatic Bile Duct Cancer Recurrent Adult Primary Liver Cancer Recurrent Extrahepatic Bile Duct Cancer Stage II Gallbladder Cancer Stage IIIA Gallbladder Cancer Stage IIIB Gallbladder Cancer Stage IVA Gallbladder Cancer Stage IVB Gallbladder Cancer Unresectable Extrahepatic Bile Duct Cancer Less << | Phase 2 | Withdrawn | - | - |
NCT01160718 | Breast Cancer | Phase 2 | Completed | - | Belgium ... More >> Universitair Ziekenhuis Gent Ghent, Belgium, B-9000 U.Z. Gasthuisberg Leuven, Belgium, B-3000 Switzerland Kantonsspital Aarau Aarau, Switzerland, CH-5001 Kantonsspital Baden Baden, Switzerland, CH-5404 Universitaetsspital-Basel Basel, Switzerland, CH-4031 Inselspital Bern Bern, Switzerland, CH-3010 Spitalzentrum Biel Biel, Switzerland, CH-2501 Kantonsspital Graubuenden Chur, Switzerland, CH-7000 Brustzentrum Thurgau at Kantonsspital Frauenfeld Frauenfeld, Switzerland, 8501 Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, CH-1011 Kantonsspital Luzern Luzerne, Switzerland, CH-6000 Oncology Institute of Southern Switzerland - Mendrisio Mendrisio, Switzerland, CH-6850 Hopital de Morges Morges, Switzerland, CH-1110 Kantonsspital - St. Gallen St. Gallen, Switzerland, CH-9007 Hopitaux Universitaires de Geneve Thonex-Geneve, Switzerland, CH-1226 Kantonsspital Winterthur Winterthur, Switzerland, CH-8400 City Hospital Triemli Zurich, Switzerland, CH-8063 Less << |
NCT01364051 | Solid Neoplasm ... More >> Stage IV Cutaneous Melanoma AJCC v6 and v7 Less << | Phase 1 | Active, not recruiting | - | United States, Florida ... More >> Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less << |
NCT02685657 | Triple Negative Breast Cancer | Phase 2 | Unknown | - | - |
NCT01333475 | Colorectal Neoplasms | Phase 2 | Completed | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
NCT01313039 | Breast Cancer | Early Phase 1 | Completed | - | United States, Florida ... More >> University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States, 33136 Less << |
NCT02151084 | Biliary Tract Carcinoma ... More >> Gallbladder Carcinoma Less << | Phase 2 | Completed | - | Canada, Ontario ... More >> Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT02337530 | Non-Small Cell Lung Cancer | Phase 2 | Active, not recruiting | December 31, 2018 | Canada, Alberta ... More >> Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia BCCA - Abbotsford Centre Abbotsford, British Columbia, Canada, V2S 0C2 BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, New Brunswick Regional Health Authority B, Zone 2 Saint John, New Brunswick, Canada, E2L 4L2 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston Kingston, Ontario, Canada, K7L 5P9 Lakeridge Health Oshawa Oshawa, Ontario, Canada, L1G 2B9 Ottawa Hospital Research Institute Ottawa, Ontario, Canada, K1H 8L6 Mount Sinai Hospital Toronto, Ontario, Canada, M5G 1X5 University Health Network Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec CHUM - Hopital Notre-Dame Montreal, Quebec, Canada, H2L 4M1 Less << |
NCT01206140 | Recurrent Adult Soft Tissue Sa... More >>rcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma Less << | Phase 2 | Completed | - | United States, California ... More >> Tower Cancer Research Foundation Beverly Hills, California, United States, 90211-1850 City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 University of California Davis Phase 2 Consortium Sacramento, California, United States, 95817 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 Less << |
NCT03259633 | NF type1 With Inoperable Plexi... More >>form Neurofibromas Less << | APPROVED_FOR_MARKETING | - | Research Site, New Orleans, Lo... More >>uisiana, 12345, United States Less << | |
NCT01206140 | - | Completed | - | - | |
NCT01333475 | - | Completed | - | - | |
NCT00604721 | - | Completed | - | - | |
NCT01217450 | Recurrent Colon Cancer ... More >> Recurrent Rectal Cancer Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << | Phase 1 | Completed | - | United States, Maryland ... More >> National Cancer Institute Medicine Branch Bethesda, Maryland, United States, 20892 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Wisconsin Clinical Cancer Center Milwaukee, Wisconsin, United States, 53226 Less << |
NCT00463814 | Tumor|Cancer | PHASE1 | ACTIVE_NOT_RECRUITING | 2025-12-31 | Research Site, Aurora, Colorad... More >>o, 80045, United States|Research Site, Nijmegen, 6525 GA, Netherlands|Research Site, Utrecht, 3584 CX, Netherlands|Research Site, Sutton, SM2 5PT, United Kingdom Less << |
NCT01362803 | Neurofibromatosis 1|Neurofibro... More >>matosis Type 1|NF1|Neurofibroma, Plexiform Less << | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | 2032-01-01 | Children's National Medical Ce... More >>nter, Washington, District of Columbia, 20010, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229-3039, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States Less << |
NCT01222689 | Adenocarcinoma of the Pancreas... More >> Recurrent Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Less << | Phase 2 | Completed | - | United States, California ... More >> UCSF-Mount Zion San Francisco, California, United States, 94115 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less << |
NCT00604721 | Adult Primary Hepatocellular C... More >>arcinoma Advanced Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer Recurrent Adult Primary Liver Cancer Less << | Phase 2 | Completed | - | United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Ohio Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 Less << |
NCT01586624 | Cancer Non Sm... More >>all Cell Lung Cancer Less << | Phase 1 | Active, not recruiting | March 2019 | United Kingdom ... More >> Cambridge Cancer Trials Centre (S4), Box 279, Addenbrooke's Hospital Hills Road, Cambridge, United Kingdom, CB2 0QQ The Christie NHS Foundation Trust Withington, Manchester, United Kingdom, M20 4BX Churchill Hospital Headington, Oxford, United Kingdom, OX3 7LJ The Freeman Hospital Newcastle, United Kingdom, NE7 7DN Less << |
NCT01222689 | - | Completed | - | - | |
NCT00551070 | - | Active, not recruiting | - | - | |
NCT00553332 | - | Completed | - | - | |
NCT00551070 | Borderline Ovarian Epithelial ... More >>Tumor Low Grade Ovarian Serous Adenocarcinoma Primary Peritoneal Carcinoma Primary Peritoneal Low Grade Serous Adenocarcinoma Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor Less << | Phase 2 | Active, not recruiting | - | - |
NCT02586987 | Lung Cancer M... More >>elanoma Head and Neck Carcinoma Gastroesophageal Cancer Breast Cancer Pancreatic Adenocarcinoma Colorectal Cancer Biliary Tract Cancer Less << | Phase 1 | Active, not recruiting | December 31, 2019 | United States, Illinois ... More >> Research Site Chicago, Illinois, United States, 60637 United States, Massachusetts Research Site Boston, Massachusetts, United States, 02215 United States, Nevada Research Site Las Vegas, Nevada, United States, 89169-3321 United States, New Jersey Research Site New Brunswick, New Jersey, United States, 8901 United States, North Carolina Research Site Charlotte, North Carolina, United States, 28204 United States, Pennsylvania Research Site Pittsburgh, Pennsylvania, United States, 15232 Less << |
NCT00553332 | Liver and Intrahepatic Biliary... More >> Tract Cancer Recurrent Extrahepatic Bile Duct Cancer Unresectable Extrahepatic Bile Duct Cancer Less << | Phase 2 | Completed | - | United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Michigan University of Michigan Cancer Center (UMCC) Research Base Ann Arbor, Michigan, United States, 48109-0352 Wayne State University Detroit, Michigan, United States, 48202 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 Less << |
NCT01519427 | Recurrent Melanoma ... More >> Stage IIIA Melanoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma Less << | Phase 2 | Terminated(Study terminated du... More >>e to slow accrual) Less << | - | United States, Georgia ... More >> Emory University Atlanta, Georgia, United States, 30322 United States, New Jersey Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Less << |
NCT01029418 | Hepatocellular Carcinoma | Phase 1 Phase 2 | Terminated(The phase II portio... More >>n was not conducted due to funding issue.) Less << | - | Singapore ... More >> National University Hospital Singapore Singapore, Singapore, 119074 National Cancer Centre Singapore Singapore, Singapore, 169610 Less << |
NCT03649165 | Neurofibromatosis Type 1 (NF1)... More >>-Related Plexiform Neurofibromas (PNs) Healthy Participants Less << | Phase 1 | Completed | - | United States, Maryland ... More >> Research Site Baltimore, Maryland, United States, 21225 Less << |
NCT02503358 | Stage IIIB Non-Small Cell Lung... More >> Cancer AJCC v7 Stage IV Non-Small Cell Lung Cancer AJCC v7 Less << | Phase 1 | Recruiting | September 1, 2019 | United States, Oregon ... More >> OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Khaled A. Tolba 503-494-8666 tolba@ohsu.edu Principal Investigator: Khaled A. Tolba Less << |
NCT01933932 | Locally Advanced or Metastatic... More >> Non Small Cell Lung Cancer Stage IIIb - IV Less << | Phase 3 | Active, not recruiting | December 31, 2018 | - |
NCT01519427 | - | Terminated(Study terminated du... More >>e to slow accrual) Less << | - | - | |
NCT01011933 | - | Completed | - | - | |
NCT01933932 | - | Active, not recruiting | - | - | |
NCT01605916 | Neoplasms,|Metastatic Cancer,|... More >>Non-Small Cell Lung Cancer|Advanced Solid Malignancies Less << | PHASE1 | COMPLETED | 2025-05-15 | Research Site, Fukuoka-shi, Ja... More >>pan|Research Site, Kashiwa-shi, Japan|Research Site, Nagoya-shi, Japan Less << |
NCT01116271 | Colorectal Cancer | Phase 2 | Completed | - | United States, California ... More >> Research Site Los Angeles, California, United States Research Site Palm Springs, California, United States United States, Colorado Research Site Aurora, Colorado, United States United States, Connecticut Research Site New Haven, Connecticut, United States United States, Delaware Research Site Newark, Delaware, United States United States, Florida Research Site Miami Beach, Florida, United States United States, New York Research Site New York, New York, United States United States, North Carolina Reserach Site Chapel Hill, North Carolina, United States Research Site Greenville, North Carolina, United States Research Site Washington, North Carolina, United States United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States United States, Washington Research Site Seattle, Washington, United States Less << |
NCT01089101 | Low Grade Glioma ... More >> Recurrent Childhood Pilocytic Astrocytoma Recurrent Neurofibromatosis Type 1 Recurrent Visual Pathway Glioma Refractory Neurofibromatosis Type 1 Refractory Visual Pathway Glioma Less << | Phase 1 Phase 2 | Recruiting | - | United States, California ... More >> Children's Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Girish Dhall 323-361-4629 Principal Investigator: Girish Dhall Lucile Packard Children's Hospital Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Michelle Monje 650-721-5750 Principal Investigator: Michelle Monje UCSF Medical Center-Mount Zion Active, not recruiting San Francisco, California, United States, 94115 UCSF Medical Center-Parnassus Recruiting San Francisco, California, United States, 94143 Contact: Anuradha Banerjee 877-827-3222 Sub-Investigator: Anuradha Banerjee Sub-Investigator: Michael D. Prados United States, Colorado Children's Hospital Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Kathleen M. Dorris 720-777-8314 Principal Investigator: Kathleen M. Dorris United States, District of Columbia Children's National Medical Center Recruiting Washington, District of Columbia, United States, 20010 Contact: Eugene I. Hwang 202-476-5046 Principal Investigator: Eugene I. Hwang United States, Illinois Lurie Children's Hospital-Chicago Recruiting Chicago, Illinois, United States, 60611 Contact: Stewart Goldman 312-227-4844 Principal Investigator: Stewart Goldman Children's Memorial Outpatient Center in Lincoln Park Active, not recruiting Chicago, Illinois, United States, 60614 United States, Maryland National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: Katherine E. Warren 301-435-4683 warrenk@mail.nih.gov Principal Investigator: Katherine E. Warren United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Ira J. Dunkel 212-639-2153 Principal Investigator: Ira J. Dunkel United States, North Carolina Duke University Medical Center Active, not recruiting Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Mariko D. DeWire-Schottmiller 513-803-1126 Principal Investigator: Mariko D. DeWire-Schottmiller United States, Pennsylvania Children's Hospital of Pittsburgh of UPMC Recruiting Pittsburgh, Pennsylvania, United States, 15224 Contact: Ian F. Pollack 412-692-5881 Principal Investigator: Ian F. Pollack United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Giles W. Robinson 901-595-2907 Principal Investigator: Giles W. Robinson United States, Texas Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Active, not recruiting Houston, Texas, United States, 77030 Texas Children's Hospital Recruiting Houston, Texas, United States, 77030 Contact: Patricia A. Baxter 832-824-4681 Principal Investigator: Patricia A. Baxter Less << |
NCT02063230 | Solid Tumors | Phase 1 | Completed | - | United States, Florida ... More >> Research Site Orlando, Florida, United States Less << |
NCT01011933 | Endometrial Adenocarcinoma ... More >> Endometrial Adenosquamous Carcinoma Endometrial Clear Cell Adenocarcinoma Recurrent Uterine Corpus Carcinoma Less << | Phase 2 | Completed | - | - |
NCT00559949 | Recurrent Thyroid Gland Carcin... More >>oma Stage I Thyroid Gland Papillary Carcinoma Stage II Thyroid Gland Papillary Carcinoma Stage III Thyroid Gland Papillary Carcinoma Stage IV Thyroid Gland Papillary Carcinoma Less << | Phase 2 | Completed | - | United States, Florida ... More >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 Canada, Ontario University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT02393690 | Metastatic Thyroid Gland Carci... More >>noma Poorly Differentiated Thyroid Gland Carcinoma Recurrent Thyroid Gland Carcinoma Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7 Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7 Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7 Less << | Phase 2 | Recruiting | August 1, 2020 | United States, California ... More >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Gerald Henderson 858-822-5223 gehenderson@ucsd.edu Principal Investigator: Gregory A. Daniels Hoag Memorial Hospital Recruiting Newport Beach, California, United States, 92663 Contact: Atessa Kiani 919-764-6586 atessa.kiani@hoag.org Principal Investigator: Michael J. Demeure United States, Colorado University of Colorado Hospital Recruiting Aurora, Colorado, United States, 80045 Contact: Paula Fisk 720-848-0676 paula.fisk@ucdenver.edu Principal Investigator: Bryan R. Haugen United States, District of Columbia MedStar Georgetown University Hospital Recruiting Washington, District of Columbia, United States, 20007 Contact: Lynette Wray 202-877-2749 lynette.wray@medstar.net Principal Investigator: Kenneth D. Burman United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Lisa Freehafer 617-643-1751 lfreehafer@partners.org Principal Investigator: Lori J. Wirth United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Mabel Ryder 855-776-0015 Ryder.Mabel@mayo.edu Principal Investigator: Mabel Ryder United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Jamie S. Walters 646-888-4450 waltersj@mskcc.org Principal Investigator: Alan L. Ho United States, North Carolina Duke University Medical Center Withdrawn Durham, North Carolina, United States, 27710 United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Mamdouh Beshara 614-292-4511 Mamdouh.Beshara@osumc.edu Principal Investigator: Jennifer A. Sipos United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Debra J. Nichols 713-792-0839 djnichols@mdanderson.org Principal Investigator: Ramona Dadu Less << |
NCT02063230 | - | Completed | - | - | |
NCT03581487 | Recurrent Non-Small Cell Lung ... More >>Carcinoma Stage IV Lung Cancer Stage IVA Lung Cancer Stage IVB Lung Cancer Less << | Phase 1 Phase 2 | Not yet recruiting | April 16, 2020 | United States, Texas ... More >> M D Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact dlgibbon@mdanderson.org Less << |
NCT02407405 | Neurofibromatosis 1 (NF1)|Plex... More >>iform Neurofibromas (PN) Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2030-01-01 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less << |
NCT00559949 | - | Completed | - | - | |
NCT00588809 | Adult Acute Myeloid Leukemia W... More >>ith t(15;17)(q22;q12) Adult Acute Promyelocytic Leukemia (M3) Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Less << | Phase 2 | Completed | - | United States, Illinois ... More >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 Less << |
NCT01635023 | Healthy Volunteers | Phase 1 | Completed | - | United States, Kansas ... More >> Reseatch Site Overland Park, Kansas, United States Less << |
NCT01061749 | Adult Solid Neoplasm | Phase 1 | Completed | - | United States, Maryland ... More >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 Less << |
NCT00588809 | - | Completed | - | - | |
NCT00888134 | Adult Solid Neoplasm | PHASE2 | COMPLETED | 2025-01-15 | Massachusetts General Hospital... More >> Cancer Center, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Massachusetts General Hospital, Charlestown, Massachusetts, 02129, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States Less << |
NCT00888134 | Adult Solid Neoplasm | PHASE2 | COMPLETED | 2025-01-15 | Massachusetts General Hospital... More >> Cancer Center, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Massachusetts General Hospital, Charlestown, Massachusetts, 02129, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States Less << |
NCT01085214 | - | Completed | - | - | |
NCT01605916 | Neoplasms,|Metastatic Cancer,|... More >>Non-Small Cell Lung Cancer|Advanced Solid Malignancies Less << | PHASE1 | COMPLETED | 2025-05-15 | Research Site, Fukuoka-shi, Ja... More >>pan|Research Site, Kashiwa-shi, Japan|Research Site, Nagoya-shi, Japan Less << |
NCT01085214 | Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less << | Phase 2 | Completed | - | United States, Florida ... More >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Mark O Hatfield-Warren Grant Magnuson Clinical Center Bethesda, Maryland, United States, 20892 National Institutes of Health Bethesda, Maryland, United States, 20892 United States, Montana Billings Clinic Cancer Center Billings, Montana, United States, 59107 United States, North Carolina University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Less << |
NCT02056392 | - | Completed | - | - | |
NCT03109301 | Neoplasms, Nerve Tissue ... More >> Neurofibromatosis 1 Heredodegenerative Disorders, Nervous System Peripheral Nervous System Diseases Less << | Phase 2 | Recruiting | February 1, 2023 | United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 Less << |
NCT01809210 | Locally Advanced or Metastatic... More >> NSCL Cancer Stage IIIB IV Less << | Phase 1 | Completed | - | United Kingdom ... More >> Research Site Glasgow, United Kingdom, G12 0YN Research Site London, United Kingdom, W1G 6AD Research Site Manchester, United Kingdom, M20 4BX Research Site Newcastle upon Tyne, United Kingdom, NE7 7DN Less << |
NCT01843062 | Differentiated Thyroid Cancer | Phase 3 | Active, not recruiting | April 29, 2019 | - |
NCT01146756 | Non Small Cell Lung Cancer | PHASE1 | COMPLETED | 2017-02-08 | The Christie NHS Foundation Tr... More >>ust, Manchester, Greater Manchester, M20 4BX, United Kingdom Less << |
NCT01783197 | Non Small Cell Lung Cancer | Phase 1 | Active, not recruiting | December 2018 | Canada, British Columbia ... More >> BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston Kingston, Ontario, Canada, K7L 5P9 Ottawa Hospital Research Institute Ottawa, Ontario, Canada, K1H 8L6 Less << |
NCT01278615 | Recurrent Adult Diffuse Large ... More >>Cell Lymphoma Less << | Phase 2 | Terminated(Closed Prematurely.... More >>) Less << | - | United States, Illinois ... More >> Northwestern University Chicago, Illinois, United States, 60611 University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 Decatur Memorial Hospital Decatur, Illinois, United States, 62526 NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States, 60201 Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 Illinois CancerCare-Peoria Peoria, Illinois, United States, 61615 Southern Illinois University Springfield, Illinois, United States, 62702 United States, Indiana Fort Wayne Medical Oncology and Hematology Inc-Parkview Fort Wayne, Indiana, United States, 46845 Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, Massachusetts Tufts Medical Center Boston, Massachusetts, United States, 02111 University of Massachusetts Memorial Health Care Worcester, Massachusetts, United States, 01605 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, Missouri Saint John's Mercy Medical Center Saint Louis, Missouri, United States, 63141 United States, New York Weill Medical College of Cornell University New York, New York, United States, 10065 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT02093728 | Solid Tumours | Phase 1 | Completed | - | United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less << |
NCT01278615 | - | Terminated(Closed Prematurely.... More >>) Less << | - | - | |
NCT01809210 | - | Completed | - | - | |
NCT02448290 | Gastric Adenocarcinoma | Phase 2 | Recruiting | October 2018 | Korea, Republic of ... More >> Samsung Medical center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Yoonjeong Ahn 82-2-2148-7395 younjeong.ahn@samsung.com Principal Investigator: Jeeyun Lee, MD,PhD Less << |
NCT03004105 | Malignant Neoplasm of Respirat... More >>ory and Intrathoracic Organ Carcinoma Advanced Lung Cancer Recurrent Nonsmall Cell Lung Cancer Less << | Phase 2 | Withdrawn(Inadequate funding) | May 2024 | - |
NCT01242605 | Biliary Tract Neoplasms ... More >> Cholangiocarcinoma Gallbladder Neoplasms Less << | Phase 1 | Completed | - | United Kingdom ... More >> Hammersmith Hospital London, United Kingdom University College London Hospital London, United Kingdom The Christie Hospital Manchester, United Kingdom Less << |
NCT02056392 | Solid Tumours | Phase 1 | Completed | - | United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less << |
NCT02188264 | Recurrent Colorectal Carcinoma... More >> Solid Neoplasm Stage IIIA Colorectal Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Less << | Phase 1 | Active, not recruiting | - | United States, California ... More >> University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Colorado University of Colorado Hospital Aurora, Colorado, United States, 80045 United States, Missouri Siteman Cancer Center at West County Hospital Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Ontario University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT03095248 | Neurofibromatosis 2|Vestibular... More >> Schwannoma|Meningioma|Ependymoma|Glioma Less << | PHASE2 | COMPLETED | 2024-05-21 | Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229, United States Less << |
NCT01949870 | Inoperable Locally Advanced or... More >> Metastatic Biliary Tract Cancer Less << | Phase 1 | Terminated(change in the devel... More >>opment strategy) Less << | - | Japan ... More >> AZD6244 PhI Japanese Gem/ Kashiwa Shi, Chiba, Japan AZD6244 PhI Japanese Gem/ Chuo Ku, Tokyo, Japan Less << |
NCT02025114 | Non-small Cell Lung Cancer (NS... More >>CLC) Less << | Phase 1 Phase 2 | Completed | - | Taiwan ... More >> National Cheng Kung University Hospital Tainan, Taiwan, 70403 Department of Oncology, National Taiwan University Hospital Taipei, Taiwan, 100 Taipei Veterans General Hospital Taipei, Taiwan, 11217 Less << |
NCT01974752 | Metastatic Uv... More >>eal Melanoma Less << | Phase 3 | Completed | - | - |
NCT01974752 | - | Completed | - | - | |
NCT03213691 | Advanced Malignant Solid Neopl... More >>asm Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma BRAF Gene Mutation GNA11 Gene Mutation GNAQ Gene Mutation Histiocytosis HRAS Gene Mutation KRAS Gene Mutation NF1 Gene Mutation NRAS Gene Mutation Recurrent Childhood Central Nervous System Neoplasm Recurrent Childhood Non-Hodgkin Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Neuroblastoma Refractory Central Nervous System Neoplasm Refractory Malignant Solid Neoplasm Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Less << | Phase 2 | Recruiting | September 30, 2024 | - |
NCT02046850 | Solid Tumours | Phase 1 | Completed | - | United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less << |
NCT02238782 | Healthy Volunteers Bioavailabi... More >>lity Study Less << | Phase 1 | Completed | - | United Kingdom ... More >> Research Site Nottingham, United Kingdom Less << |
NCT02839720 | Appearance Distress ... More >> Bothered by Itching Skin Cafe Au Lait Spot Cutaneous Neurofibroma Disfigurement Dysplasia Lisch Nodule Neurofibromatosis Type 1 NF1 Gene Mutation Optic Nerve Glioma Less << | Phase 2 | Recruiting | December 31, 2018 | United States, Alabama ... More >> University of Alabama at Birmingham Cancer Center Recruiting Birmingham, Alabama, United States, 35233 Contact: Bruce R. Korf 205-934-9411 bkorf@uabmc.edu Principal Investigator: Bruce R. Korf United States, Maryland National Institutes of Health Clinical Center Not yet recruiting Bethesda, Maryland, United States, 20892 Contact: Brigitte C. Widemann 301-496-0738 ext 7 widemanb@mail.nih.gov Principal Investigator: Brigitte C. Widemann United States, Texas UT Southwestern/Simmons Cancer Center-Dallas Not yet recruiting Dallas, Texas, United States, 75390 Contact: Lu Q. Le 214-648-7097 lu.le@utsouthwestern.edu Principal Investigator: Lu Q. Le Less << |
NCT02238782 | - | Completed | - | - | |
NCT02063204 | Solid Tumours | Phase 1 | Completed | - | United States, Florida ... More >> Research Site Orlando, Florida, United States Less << |
NCT02322749 | Healthy Volunteers Bioequivale... More >>nce or Bioavailability Study Less << | Phase 1 | Completed | - | United Kingdom ... More >> Research Site London, United Kingdom Less << |
NCT03392246 | Non-small Cell Lung Cancer | Phase 2 | Recruiting | June 30, 2025 | United States, Massachusetts ... More >> Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02214 Contact: Zofia Piotrowska, MD zpiotrowska@partners.org Principal Investigator: Zofia Piotrowska, MD Beth Israel Deaconess Medical Center Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Daniel Costa, MD dbcosta@bidmc.harvard.edu Principal Investigator: Daniel Costa, MD Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Sarah E Clifford 617-632-5438 SarahE_Clifford@DFCI.HARVARD.EDU Principal Investigator: Pasi A Janne, MD Less << |
NCT02322749 | - | Completed | - | - | |
NCT01960374 | Healthy Volunteers Pharmacokin... More >>etic Study Less << | PHASE1 | COMPLETED | 2025-05-14 | Research Site, London, United ... More >>Kingdom Less << |
NCT01931761 | Solid Tumours | Phase 1 | Completed | - | United Kingdom ... More >> Research Site Ruddington, United Kingdom Less << |
NCT02583542 | Triple-Negative Breast Cancer ... More >> Squamous Cell Lung Cancer Non-squamous Cell Lung Cancer With KRAS Mutations Non-squamous Cell Lung Cancer With Wild-type KRAS Less << | Phase 1 Phase 2 | Recruiting | July 2019 | United Kingdom ... More >> University Hospitals Birmingham NHS Foundation Trust Recruiting Birmingham, United Kingdom, B15 2TT Contact: Gary Middleton, Professor +44 (0) 1213713573 Gary.Middleton@uhb.nhs.uk Contact: Ceri Amstrong +44 (0) 1214143795 c.j.armstrong@bham.ac.uk Principal Investigator: Gary Middleton, Professor Barts Health NHS Trust Recruiting London, United Kingdom, EC1M 6BQ Contact: Peter Schmid +44 (0)20 7882 8498 p.schmid@qmul.ac.uk Contact: Louise Lim farahlouise.lim@bartshealth.nhs.uk Principal Investigator: Peter Schmid Sub-Investigator: Louise Lim University College London Hospitals NHS Foundation Trust Recruiting London, United Kingdom, W1T 7HA Contact: Martin Forster, Dr +44 (0) 2034475085 Martin.Forster@uclh.nhs.uk Contact: Magda Rocha +44 (0) 2034472921 Magda.PintoRocha@uclh.nhs.uk Principal Investigator: Martin Forster, Dr Christie NHS Foundation Trust Recruiting Manchester, United Kingdom, M20 4BX Contact: Yvonne Summers, Dr +44 (0) 161 446 8016 yvonne.summers@christie.nhs.uk Contact: Rachael Finney +44 (0) 1619182318 rachael.finney@christie.nhs.uk Principal Investigator: Yvonne Summers, Dr Less << |
NCT03040986 | KRAS NP_004976.2:p.G12R ... More >> Stage III Pancreatic Cancer AJCC v6 and v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Less << | Phase 2 | Suspended(Interim monitoring) | December 31, 2021 | United States, California ... More >> Los Angeles County-USC Medical Center Los Angeles, California, United States, 90033 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Kentucky University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States, 40536 United States, Maryland NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 Less << |
NCT01949870 | - | Terminated(change in the devel... More >>opment strategy) Less << | - | - | |
NCT01974349 | Solid Tumours | Phase 1 | Completed | - | United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less << |
NCT03162627 | Malignant Neoplasm of Breast ... More >> Malignant Neoplasms of Digestive Organs Malignant Neoplasms of Female Genital Organs Malignant Neoplasms of Male Genital Organs Malignant Neoplasms of Thyroid and Other Endocrine Glands Less << | Phase 1 | Recruiting | August 2026 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact swestin@mdanderson.org Less << |
NCT03705507 | Acute Lymphoblastic Leukemia ... More >> Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia, in Relapse Acute Lymphoblastic Leukemia Recurrent Less << | Phase 1 Phase 2 | Recruiting | March 17, 2021 | United Kingdom ... More >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom Principal Investigator: Alice Norton Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom Principal Investigator: Mark Caswell Department of Paediatric Oncology, Royal Marsden Hospital, Sutton Recruiting London Borough of Sutton, United Kingdom Principal Investigator: Donna Lancaster Haemato-Oncology Adult Unit, Royal Marsden Hospital, Sutton Recruiting London Borough of Sutton, United Kingdom Sub-Investigator: David Taussig University College Hospital Recruiting London, United Kingdom Principal Investigator: Adele Fielding The Christie Hospital Recruiting Manchester, United Kingdom Principal Investigator: Anna Castleton Freeman Hospital Recruiting Newcastle, United Kingdom Sub-Investigator: Tobias Menne Great North Children's Hospital, Royal Victoria Infirmary Recruiting Newcastle, United Kingdom Principal Investigator: Geoff Shenton Less << |
NCT01752569 | AIDS-related Kaposi's Sarcoma | PHASE1|PHASE2 | TERMINATED | 2017-12-20 | Brighton and Sussex University... More >> Hospitals, Brighton, BN2 5BE, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Royal Free Hospital, London, NW3 2QG, United Kingdom|Chelsea & Westminster Hospital, London, SW10 9NH, United Kingdom|The Christie Hospital, Manchester, M20 4BX, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2SJ, United Kingdom Less << |
NCT03745989 | Solid Tumors | Phase 1 | Not yet recruiting | May 6, 2022 | - |
NCT03433183 | Malignant Peripheral Nerve She... More >>ath Tumors Neurofibromatosis 1 Less << | Phase 2 | Not yet recruiting | September 2021 | - |
NCT03326388 | Neurofibromatosis Type 1|Plexi... More >>form Neurofibroma|Optic Nerve Glioma Less << | PHASE1|PHASE2 | COMPLETED | 2024-02-14 | Great Ormond Street Hospital f... More >>or Children NHS Foundation Trust, London, wc1n 1eh, United Kingdom|Great Ormond Street Hospital NHS Foundatin Trust, London, WC1N 3JH, United Kingdom Less << |
NCT02768766 | Uveal Melanoma | Phase 1 | Recruiting | January 2019 | United States, New York ... More >> Columbia University Medical Center Recruiting New York, New York, United States, 10032 Contact: Richard Carvajal, MD rdc2150@cumc.columbia.edu Principal Investigator: Richard Carvajal, MD Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Alexander N Shoushtari, M.D 646-888-4161 shoushta@mskcc.org United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Sapna Patel, M.D 713-792-4955 sppatel@mdanderson.org Less << |
NCT03326310 | Chronic Myeloid Leukemia ... More >> Myelofibroses Less << | Phase 1 | Recruiting | September 4, 2023 | United States, Illinois ... More >> The University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Melissa Fridstein 773-702-9885 mfridstein@medicine.bsd.uchicago.edu Less << |
NCT02450656 | Colorectal Neoplasms ... More >> Gastrointestinal Neoplasms Pancreatic Neoplasms Carcinoma, Non-Small-Cell Lung Less << | Phase 1 Phase 2 | Recruiting | December 2019 | Netherlands ... More >> UMC St. Radboud Nijmegen Recruiting Nijmegen, Gelderland, Netherlands, 6525GA Contact: Carla ML van Herpen, MD, PhD +31243610353 Carla.vanHerpen@radboudumc.nl Principal Investigator: Carla ML van Herpen, MD, PhD Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066CX Contact: F Opdam, MD, PhD Principal Investigator: F Opdam, MD, PhD Less << |
NCT04495127 | Neurofibromatosis Type 1 | PHASE1 | COMPLETED | 2023-03-24 | Research Site, Minato-ku, 105-... More >>8471, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Setagaya-ku, 157-8535, Japan Less << |
NCT05253131 | MPNST|NF1|Sarcoma | PHASE2 | NOT_YET_RECRUITING | 2031-06-15 | The University of Alabama at B... More >>irmingham, Birmingham, Alabama, 35294, United States|Children's Hospital Los Angeles, Los Angeles, California, 90027, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|University of Chicago, Chicago, Illinois, 60637, United States|Indiana University, Indianapolis, Indiana, 46202, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|National Cancer Institute (NCI), Bethesda, Maryland, 20892, United States|Mayo Clinic, Minneapolis, Minnesota, 56001, United States|Washington University - St. Louis, Saint Louis, Missouri, 63110, United States|New York University Medical Center, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229-3039, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19096, United States|Childrens Medical Center - Univ. of Texas SW, Dallas, Texas, 75235, United States Less << |
NCT06621082 | Neurofibromatosis 1 | PHASE2 | NOT_YET_RECRUITING | 2026-12-31 | - |
NCT06620354 | Neurofibromatosis 1 | PHASE2 | NOT_YET_RECRUITING | 2026-12-31 | - |
NCT06763315 | Plexiform Neurofibromas (PN) | PHASE2 | NOT_YET_RECRUITING | 2028-10-31 | West China Hospital of Sichuan... More >> University, Chengdu, Sichuan, 610041, China Less << |
NCT05101148 | Neurofibromatosis Type 1 | PHASE1 | ACTIVE_NOT_RECRUITING | 2026-01-12 | Research Site, Rochester, Minn... More >>esota, 55905, United States|Research Site, Akron, Ohio, 44308, United States|Research Site, Bydgoszcz, 85-094, Poland|Research Site, Gdańsk, 80-952, Poland|Research Site, Warszawa, 02-091, Poland|Research Site, Moscow, 119620, Russian Federation|Research Site, Moscow, 125412, Russian Federation|Research Site, Barcelona, 08950, Spain|Research Site, Madrid, 28009, Spain Less << |
NCT04590235 | Neurofibromatosis 1|Neurofibro... More >>ma Plexiform Less << | PHASE1 | ACTIVE_NOT_RECRUITING | 2026-08-31 | Research Site, Shanghai, 20001... More >>1, China|Research Site, Shanghai, CN-200092, China Less << |
NCT06188741 | Neurofibromatosis 1|Plexiform ... More >>Neurofibroma Less << | PHASE2 | NOT_YET_RECRUITING | 2032-03-01 | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.18mL 0.44mL 0.22mL |
10.92mL 2.18mL 1.09mL |
21.85mL 4.37mL 2.18mL |